PTC Therapeutics announced that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington’s disease. Fast Track designation is awarded to promising therapies for diseases of high unmet need.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics selloff ‘not warranted,’ says Morgan Stanley
- PTC Therapeutics initiated with an Outperform at Baird
- ClearPoint Neuro price target raised to $15 from $11 at Lake Street
- Boeing’s Starliner to return without astronauts: Morning Buzz
- Kymera upgraded, MoonLake downgraded: Wall Street’s top analyst calls